Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%

Healthcare

Page 78
  1. Jan 07, 2026 · 08:51 · VPT

    Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

    Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

    01
  2. Jan 07, 2026 · 07:00 · MBX

    Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing

    Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing

    02
  3. Jan 06, 2026 · 20:18 · VIVI

    Tempramed receives first order in Israel

    Tempramed receives first order in Israel

    03
  4. Jan 06, 2026 · 19:32 · DRUG

    Bright Minds arranges $10M (U.S.) public offering

    Bright Minds arranges $10M (U.S.) public offering

    04
  5. Jan 06, 2026 · 17:09 · PRN

    Profound sees first Johns Hopkins Tulsa case

    Profound sees first Johns Hopkins Tulsa case

    05
  6. Jan 06, 2026 · 17:01 · VIVI

    TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network

    TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network

    06
  7. Jan 06, 2026 · 16:35 · DRUG

    Bright Minds' BMB-101 phase 2 shows seizure declines

    Bright Minds' BMB-101 phase 2 shows seizure declines

    07
  8. Jan 06, 2026 · 16:00 · DRUG

    Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

    Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

    08
  9. Jan 06, 2026 · 12:32 · LOBE

    Lobe Sciences has cash of $5.85-million at Aug. 31

    Lobe Sciences has cash of $5.85-million at Aug. 31

    09
  10. Jan 06, 2026 · 09:00 · 4875

    2026 New Year's Greetings from the CEO

    2026 New Year's Greetings from the CEO

    10
  11. Jan 06, 2026 · 08:29 · 4543

    Terumo Launches SurTract(TM) Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR(TM) Passive Safety Technology

    Terumo Launches SurTract(TM) Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR(TM) Passive Safety Technology

    11
  12. Jan 06, 2026 · 07:45 · PRN

    Johns Hopkins Medicine Treats First Commercial TULSA-PRO(TM) Case

    Johns Hopkins Medicine Treats First Commercial TULSA-PRO(TM) Case

    12
  13. Jan 06, 2026 · 06:00 · LOBE

    Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

    Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

    13
  14. Jan 05, 2026 · 20:48 · DRUG

    Bright Minds to discuss BMB-101 phase 2 trial Jan. 6

    Bright Minds to discuss BMB-101 phase 2 trial Jan. 6

    14
← Newer Older →